Volume : 08, Issue : 06, June – 2021
Title:
29.LONG TERM MANAGEMENT OF CYSTIC FIBROSIS
Authors :
Mohammed Saeed Alghamdi, Osama Abduallah Alzahrani, Ali mohammed alghamdi, Abdullah solaiman m aloraini
Abstract :
Introduction: Cystic fibrosis (CF) is a lung disease that involves more than 80,000 people globally. It is a life-threatening genetic disorder characterized by the buildup of thick, viscous mucus secretions in various organ systems, most commonly the pulmonary, gastrointestinal, and genitourinary systems. This article reviews the long-term management of cystic fibrosis
Aim of the study: The review aims to understand clinical manifestations of cystic fibrosis, its diagnosis, and monitoring of patients, as well as guidelines for management and emerging pharmacologic treatments.
Methodology: The review is a comprehensive research of PUBMED from year to 1990 to 2008.
Conclusion: There is an immense improvement in the management of cystic fibrosis, especially after approval of CFTR modulators, but it is still in question since management of cystic fibrosis not only the protein rectifiers but also symptomatic treatment and intensive physiotherapy, which require concomitant therapies. The genotype myriad also poses a challenge, and most correcting drugs are for children older than 12 years of age. Most of these drugs have serious hepatic toxicity and other side effects. The psychological and social burden of disease should also need to be concerned.
Keywords: Cystic fibrosis, antimicrobials, nutritional therapy, respiratory status
Cite This Article:
Please cite this article in press Mohammed Saeed Alghamdi et al., Long Term Management Of Cystic Fibrosis .., Indo Am. J. P. Sci, 2021; 08(06).
Number of Downloads : 10
References:
1. Dodge J A, Lewis P A, Stanton M, & Wilsher J (2007). Cystic fibrosis mortality and survival in the UK: 1947–2003. European Respiratory Journal, 29(3), 522-526.
2. Riordan J R, Rommens J M, Kerem B S, Alon N, Rozmahel R, Grzelczak Z, & Chou J L (1989). Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science, 245(4922), 1066-1073.
3. Bardin E E, Cameron S J, Perdones-Montero A, Hardiman K, Bolt F, Alton E W, & Takáts Z (2018). Metabolic phenotyping and strain characterisation of Pseudomonas aeruginosa isolates from cystic fibrosis patients using rapid evaporative ionisation mass spectrometry. Scientific reports, 8(1), 1-10.
4. Fernald G W, Roberts M W, & Boat T F (1990). Cystic fibrosis: a current review. Pediatr Dent, 12(2), 72-8.
5. Osadnik, C. R., Tee, V. S., Carson‐Chahhoud, K. V., Picot, J., Wedzicha, J. A., & Smith, B. J. (2017). Non‐invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews, (7).
6. King C S, Brown A W, Aryal S, Ahmad K, & Donaldson S (2019). Critical care of the adult patient with cystic fibrosis. Chest, 155(1), 202-214.
7. Chhajed P N, Aboyoun C, Chhajed T P, Malouf M A, Harrison G A, Tamm M, & Glanville A R (2005). Sedative drug requirements during bronchoscopy are higher in cystic fibrosis after lung transplantation. Transplantation, 80(8), 1081-1085.
8. Lai H C, Corey M, FitzSimmons S, Kosorok M R, & Farrell P M (1999). Comparison of growth status of patients with cystic fibrosis between the United States and Canada. The American journal of clinical nutrition, 69(3), 531-538.
9. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, & Thomas W (2009). Cystic fibrosis–related diabetes: current trends in prevalence, incidence, and mortality. Diabetes care, 32(9), 1626-1631.
10. Flume P A, Mogayzel Jr P J, Robinson K A, Goss C H, Rosenblatt R L, Kuhn R J, & Clinical Practice Guidelines for Pulmonary Therapies Committee* (2009). Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. American journal of respiratory and critical care medicine, 180(9), 802-808.